Syntegon-equipped WuXi XDC site in Singapore secures GMP release

WuXi XDC's new antibody-drug conjugate manufacturing site at Tuas Biomedical Park in Singapore has achieved GMP release, using filling line and isolator equipment supplied by Syntegon. The site's BCM3 production line and DP4 facility received GMP approval in August 2026, supporting the CDMO's manufacturing expansion in Southeast Asia.

Why this mattersGMP release validates Syntegon's filling and isolator equipment at an Asian bioconjugate CDMO, a reference point for further pharmaceutical capacity awards in Southeast Asia.

• WuXi XDC's Singapore site at Tuas Biomedical Park achieved GMP release
• The BCM3 production line and DP4 facility received GMP approval in August 2026
• Syntegon supplied filling line and isolator technology to the site
• Syntegon's filling line reaches speeds of up to 300 vials per minute using hydrogen peroxide bio-decontamination
• The Singapore site was first announced in 2024
• Systems are integrated through a unified automation control platform to cut downtime and maintenance costs

Relevant to you? Yes No